NCT04169022

AML Cell Immunotherapy Using Chimeric Antigen Receptor T-cells

Targeting Interleukin 1 Receptor Accessory Protein (IL1RAP) Expressing Acute Myeloid Leukemic (AML) Cells by Chimeric Antigen Receptor (CAR) Engineered T-cells

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 86 (actual)
• Sponsor: Centre Hospitalier Universitaire de Besancon · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

AML is one of the most aggressive forms of leukemia, where bone marrow transplantation remains the gold standard treatment, with its known associated toxicities and related mortality. Despite progress in the treatment of leukemic malignancies, especially the emergence of targeted- and immuno-therapies arising from biological genomic knowledge, there remains a need to provide additional strategies for refractory/relapsing (R/R) patients Aim of this study is to collect biological samples of AML patients in order to validate our Chimeric Antigen Receptor T-cells immunotherapy approach

Conditions

• Acute Myeloid Leukemia

Interventions

Type	Name	Description
OTHER	Sample collection	Sample collection blood and/or bone marrow

Timeline

• Start date: 2019-07-10
• Primary completion: 2023-10-02
• Completion: 2023-10-02
• First posted: 2019-11-19
• Last updated: 2024-02-12

Locations

1 site across 1 country: France